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Abstract
We demonstrate that rapamycin can induce regression of adenomatous polyposis coli (Apc) mutation–dependent
colonic adenomas in genetically engineered mice (CPC;Apc). An endoscope was used to visualize adenomas in
CPC;Apc mice weekly for 10 weeks. The lesion surface areas were measured using a distance gauge and digitally
generated grid. Coronal scans were performed on magnetic resonance imaging (MRI) to localize adenomas, and tu-
mor volumes were measured from regions of interest drawn on consecutive axial scans. Rapamycin (5 mg/kg) was
administered intraperitoneally daily for 5 weeks. Endoscopy and MRI were performed weekly to monitor adenoma
regression. Caliper measurements and immunohistochemistry (IHC) were performed on adenomas postmortem.
Dimensions from n = 30 adenomas in n = 7 animals were measured. Adenoma surface areas on endoscopy corre-
lated with volumes on MRI and with postmortem caliper measurements, R2 = 0.84 and R2 = 0.81, respectively. The
mean adenoma doubling times on endoscopy and MRI were 0.95 ± 0.14 and 1.21 ± 0.16 weeks, respectively. The
minimum detectable adenoma surface area and volume on endoscopy and MRI was 0.69 mm2 and 1.76 mm3, re-
spectively. On histology, the rapamycin-treated adenomas showed limited regions of dysplasia. Rapamycin therapy
resulted inmuch lowermammalian target of rapamycin signaling and cell proliferation. Lower expression of phospho-S6
and reduced numbers of Ki67-positive cells were seen on IHC compared to vehicle-treated lesions. Endoscopy can be
validated by MRI as a robust methodology for quantitative monitoring of therapy, representing a promising approach
for future preclinical efforts to assess utility of novel colorectal cancer prevention strategies.
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Introduction
Quantitative multimodal imaging uses the physical characteristics of
one imaging system to validate the performance of another [1].
Minimally invasive optical methods, such as endoscopy, are being
combined with established whole-body techniques, such as MRI [2],
as multimodal strategies to evaluate novel cancer therapeutics [3].
Colorectal cancer is a major cause of cancer-related death [4], and
the removal of adenomas on screening with white light endoscopy
can significantly reduce mortality [5]. Mutations in the adenomatous
polyposis coli (Apc) gene are widely believed to play a critical role in
the initiation of adenoma formation in humans [6]. The ApcMin mouse
model develops adenomas primarily in the small intestine [7] but often
dies from intussusception or anemia by 120 days of age. Previous
preclinical studies have shown the use of MRI colonography to iden-
tify and track adenoma growth using chemical induction of colonic
adenomas [8,9] or a unique strain of ApcMin mouse [2,10]. Another
study required labor-intensive surgery to generate colonic adenomas
for monitoring tumor regression with serial colonoscopy [11]. These
studies do not report generalized approaches and methods for quanti-
tative temporal analyses of adenoma regression in response to therapy.
Several mouse models with germline or somatic mutations in the Apc
gene, e.g., germline ApcMin and conditional CDX2P-NLSCre Apc f lox/+
(CPC;Apc), allow for in-depth studies of colonic tumor development
[12,13]. The molecular pathway for adenoma development in the
CPC;Apc mouse is initiated by somatic inactivation of a second Apc
allele, resulting in increased levels of β-catenin and activation of the
canonical Wnt signaling pathway (Figure 1A). CPC;Apc mice develop
between 4 and 10 adenomas in the distal colon and rectum [14], a
location compatible with endoscopy [15]. Because the CPC;Apc and
other mouse models can manifest a multiplicity of adenomas in rela-
tively small portions of the colon [14], the previously reported tech-
nique of lumen distension as a surrogate measure of tumor size may
not be accurate [11]. The mammalian target of rapamycin (mTOR)
is a serine/threonine kinase that regulates cell growth and is activated
in colorectal cancer, producing increased downstream expression of
phospho-S6K and phospho-S6 (Figure 1A) [16–18]. Two signaling
complexes containing mTOR (mTORC1 and mTORC2) individually
act to regulate cell growth, in part as evidenced through the phos-
phorylation of S6 kinase or being involved in Akt phosphorylation
and regulation of the actin cytoskeleton, respectively [19,20].
Previous studies have reported that the mTOR inhibitors, including
rapamycin and everolimus, can antagonize the growth of small intes-
tinal adenomas [21,22]. However, either no effects of rapamycin [21]
or no clear results [22] were found for colonic adenomas. Moreover, a
previous study evaluated endoscopically the response of colonic adeno-
mas to 5-fluorouracil therapy and found regression in a fraction of
tumors [23]. Here, we aim to characterize the temporal growth of
individual adenomas over time in CPC;Apc mice using multimodal
imaging with endoscopy and MRI. We also aim to demonstrate that
rapamycin can induce regression of established colonic adenomas
Figure 1. Multimodal imaging strategy. (A) Schematic shows the relationship between molecular markers expressed in activated mTOR
signaling pathway. (B) Distance from endoscope to adenoma (arrow) is measured in vivo with gauge (arrowhead) passed through the
instrument channel. (C) Grid (1 × 1 mm2 squares) is digitally overlaid onto the endoscopic image for measuring long and short axes of
adenoma (arrow). (D) T1-weighted coronal MRI scan (low resolution) identifies anatomic landmarks to localize adenoma, defining a window
(dashed lines) for axial scans (high resolution). (E) Adenoma (arrow) dimensions (a, b, and c) are validated ex vivo with calipers.
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as a chemoprevention strategy and use tumor dimensions measured
onMRI to validate performance on endoscopy over the duration of ther-
apy. The effectiveness of rapamycin therapy is assessed on histology for
regions of dysplastic epithelial glands and on immunohistochemistry
(IHC) for evidence of reduced mTOR pathway signaling and cell pro-
liferation. The ability to assess adenoma growth and drug-induced re-
gression quantitatively and temporally in a genetic mouse model
of colon tumorigenesis has major implications for future preclinical
efforts to assess utility of novel colorectal cancer prevention and treat-
ment approaches.
Materials and Methods
Mouse Model of Colorectal Cancer
Mice were provided internally (E.R.F.) and cared for under the ap-
proval of the institutional University Committee on the Use and Care
of Animals. The CPC;Apcmice carry a Cre recombinase transgene regu-
lated by human CDX2 promoter elements (CDX2P-9.5NLS-Cre) and a
floxed allele of the Apc gene and were developed on a C57BL6/J genetic
background [14]. CDX2-regulated, Cre-mediated targeting of the Apc
allele leads to the production of a truncated Apc protein [24] and the
development of adenomas and early carcinomas in the distal colon and
rectum over a 10- to 40-week period [14]. All mice were housed in
specific pathogen-free conditions and supplied water ad libitum through-
out the study. Mice were 3 months old at the beginning of the study.
Endoscopy Procedure
The colon was prepped by delivering tap water rectally using a trans-
fer pipette. A small animal endoscope (Karl Storz Veterinary Endoscopy,
Goleta, CA) with 0° viewing angle and a 3 Fr instrument channel was
used to identify and measure all visible adenomas [25]. Mice were
anesthetized, and sedation was maintained with 1.5% isoflurane using
a nose cone during endoscopy.When an adenoma (arrow) was identified
in vivo (Figure 1B), a gauge (arrowhead), calibrated in 1-mm increments,
was passed through the instrument channel to measure the distance to
the lesion surface. An image of a grid with 1 × 1 mm2 squares was col-
lected with the endoscope at various distances away. Given this distance,
the appropriate grid was then digitally overlaid onto the image to mea-
sure the long and short axes of the adenoma to within 0.25-mm accu-
racy, using Matlab software (Mathworks, Natick, MA; Figure 1C). The
short- and long-axis measurements for each adenoma were used to
calculate the adenoma surface area as πab (a = radius of long axis, b =
radius of short axis). The distal end of the endoscope was calibrated at
1-cm increments. Mice underwent endoscopy each week for 10 weeks
to assess adenoma growth and for 5 weeks to evaluate response of
adenomas to rapamycin therapy.
MRI Procedure
Immediately after completing endoscopy, the mice were scanned in
a Varian 7 Tesla horizontal bore MRI. A Varian 108 mm × 63 mm
quad coil was used. Mice were anesthetized and maintained at 1.5%
isoflurane using a nose cone inside the coil for the duration of the
MRI scan. Before entering the coil, mice were placed on a custom-
fabricated plastic bed and given a subcutaneous injection with 0.025 ml
of 0.5 M gadopentetate dimeglumine (Magnevist, Bayer HealthCare
Pharmaceuticals Inc., Wayne, NJ; NDC 50419-188-46). The lumen
of the colon was distended using a programmable infusion pump
(PHD2000, Harvard Apparatus, Holliston, MA). A flexible catheter
was placed into the rectum approximately 1 cm from the anus and
taped to the tail for stability. Fluorinert was infused (0.05 ml/min)
before scanning and during the scan. Coronal and axial T1-weighted
scans were collected from each mouse. For coronal acquisition, the
following parameters were used: repetition time/echo time (TR/TE),
750/20; 1 average; 20 slices; 0.5 mm thick; display matrix, 128 ×
128; field of view, 50 mm × 25 mm. This view was used to determine
the approximate location of the adenoma to perform the axial scan
(Figure 1D, dashed lines). For axial acquisition, the following param-
eters were used: TR/TE, 1450/20; 1 average; 40 slices; 1.0 mm thick;
matrix size, 128 × 128; field of view, 25mm × 25mm. Tumor volumes
were calculated by drawing a region of interest (ROI) around each
adenoma on consecutive axial slices, summing the areas of the ROI,
and multiplying by the slice thickness. Mice underwent MRI every
other week for 10 weeks to assess adenoma growth and every week
for 5 weeks to evaluate response to therapy.
Ex Vivo Validation
Mice being monitored for adenoma (arrow) growth were euthanized
after completion of imaging, and the colon of each mouse was excised,
exposing the mucosal surface, as shown in Figure 1E . Vernier calipers
were used to measure the width (a), length (b), and height (c) of the
adenoma to calculate the approximate postmortem surface area (πab)
and volume (4πabc/3) for comparison with the results on endoscopy
and MRI, respectively. The data were linearized by dividing the size
of the adenoma at each time point by its initial size in week 0 and then
taking the natural log. The doubling time for each adenoma was
calculated by taking the slope of the linearized data.
Rapamycin Administration
Rapamycin was first dissolved in 200 proof ethanol to create a
20 mg/ml stock solution, which was then diluted with 5% Tween 80/
PEG 400 solution (Tween 80 #P1754 and PEG 400 #P3265; Sigma-
Aldrich, St Louis, MO). Mice at ages 5 to 6 months were given 5 mg/kg
rapamycin (#R0395, Sigma-Aldrich) through intraperitoneal (i.p.)
injection daily (7×/week) for 35 days.
Histology
All tissues were fixed in phosphate-buffered formalin for 24 hours,
paraffin-embedded, sectioned into 10-μm thin slices, and stained
with hematoxylin and eosin (H&E).
IHC and Western Blot Analysis
Sections of formalin-fixed and paraffin-embedded mouse colon
tissues were subjected to immunohistochemical analysis [26] using
the following primary antibodies: mouse anti–total β-catenin (1:800;
BD Transduction Laboratories, San Jose, CA), rat anti-Ki67 (1:500;
Dako, Carpinteria, CA), and rabbit anti–phospho-S6 (Ser235/236;
1:200; clone 91B2, Cell Signaling Technology, Danvers, MA). All
Western blot analyses were done as described previously [26] using
the following antibodies: mouse anti–total β-catenin (1:800; BD
Transduction Laboratories), rabbit anti–phospho-S6 (Ser235/236;
1:1000; clone 91B2, Cell Signaling Technology), mouse anti–total
S6 (1:1000; clone 54D2, Cell Signaling Technology), rabbit anti–
phospho-p70 S6 kinase (1:1000; clone 91B2, Cell Signaling Technol-
ogy), rabbit anti–total S6 kinase (1:1000, Santa Cruz Biotechnology,
Santa Cruz, CA), and mouse anti–β-actin (1:10000; Sigma).
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Statistics
A two-tailed Pearson’s correlation was used to compare adenoma
dimensions on endoscopy and MRI (PASW Statistics 18, Chicago,
IL). All results are reported as SEM unless otherwise noted.
Results
Imaging of Adenoma Growth and Regression
Dimensions from n = 30 adenomas in n = 7 animals at distances of
0.5 to 4 cm from the anus were measured on endoscopy. Growth of a
representative adenoma on endoscopy is shown every other week over a
period of 10 weeks (Figure 2A). The adenoma (arrow) expands rapidly
in size over this period of time. The same adenoma (red line) is shown
on T1-weighted axial MRI at the same time points (Figure 2B). The
arrowhead identifies the periphery of the colonic wall. The mean
adenoma doubling times on endoscopy and MRI were found to be
0.95 ± 0.14 and 1.21 ± 0.16 weeks, respectively.
Animals (n = 10) were treated with 5 mg/kg rapamycin adminis-
tered i.p. daily (7 days/week) for 5 weeks. The response of a repre-
sentative adenoma to rapamycin therapy over a 4-week period on
endoscopy is shown (Figure 2C ). The adenoma (arrow) is seen to
regress in size considerably over this period of time. The same adenoma
(purple line) is shown on T1-weighted axial MRI at identical time
points (Figure 2D). In total, n = 24 adenomas were studied. Mice that
received rapamycin showed no adverse physical signs.
Analysis of Adenoma Growth and Regression
The surface areas of adenomas measured in vivo on endoscopy are
compared with that evaluated postmortem with calipers (R2 = 0.84,
Figure 2.Monitoring of adenoma growth and regression. (A) In vivo adenoma growth (arrow) on endoscopy is shown over 10weeks. (B) The
same adenoma is shown on T1-weighted axial MRI performed at the same time points. The ROI (red) drawn around the adenoma is used
to measure tumor volume. Arrowhead identifies colonic wall. (C) Adenoma regression in response to rapamycin therapy is shown on
endoscopy over 4 weeks. (D) The same adenoma is shown on T1-weighted axial MRI with ROI (purple) drawn to measure tumor volume.
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Figure 3A), and the volume of adenomas measured in vivo on MRI are
compared with that evaluated postmortem with calipers (R2 = 0.81,
Figure 3B). The minimum adenoma surface area measured on endos-
copy was 0.88 mm2 compared to 0.47 mm2 on calipers. The minimum
adenoma volume detectable on MRI was 1.76 mm3 compared to
0.31 mm3 on calipers. These values were determined by the smallest
adenoma dimensions first seen for each modality. A comparison of
adenoma growth rates in percent change (%Δ) on endoscopy and MRI
is shown (R2 = 0.73, Figure 3C ). A Pearson’s correlation of ρ = 0.836
(P < .001) indicates significance.
After 5 weeks of rapamycin therapy, all adenomas monitored were
found to regress in size, and 5 of 24 adenomas were too small to be
detected with either imaging technique. No carcinomas were found
in this cohort of mice. A comparison of adenoma regression rate in
percent change (%Δ) on endoscopy and MRI in response to rapamycin
therapy is shown (R2 = 0.40, Figure 3D).
Rapamycin Inhibits mTOR Signaling and Reduces Tumor
Proliferation in Adenomas
IHC analysis from representative low magnification images of
normal (control) distal colonic mucosa and adenoma with β-catenin
(left, middle panels) and phospho-S6 (right panels) are shown (Fig-
ure 4A). The boxed areas from the left panels (scale bars, 50 μm)
are shown in high magnification in the middle panels (scale bar,
25 μm). Increased expression of β-catenin and phospho-S6 can be
appreciated in the adenoma.
Histology (H&E) of normal (control) distal colonic epithelium and
adenoma treated with rapamycin (left panels) and vehicle (right panels) is
shown (Figure 4B; scale bars, 100 μm). The boxes in the bottom panels
show regions of dysplasia that were further studied on IHC. Signifi-
cant levels of β-catenin expression were observed in the adenomas in
both the rapamycin-treated and vehicle-treated adenomas (Figure 4C ,
left panels). The level of expression of phospho-S6 ribosomal protein
was found to be lower in a residual adenoma from the rapamycin-
treated mouse compared to that for the vehicle-treated mouse (Fig-
ure 4C , middle panels). This result reflects reduced mTOR pathway
signaling and is supported by the observation of a significant reduction
in Ki67-labeled cells in rapamycin-treated adenomas compared to
vehicle-treated adenomas (Figure 4C , right panels; scale bars, 50 μm).
These results are validated on Western blot analysis of β-catenin,
phospho-p70 S6 kinase (phospho-S6K), total S6K, phospho-S6, total
S6, and β-actin (control) of normal colonic mucosa and adenomas
from two normal (control) wild-type mice (normal1 and normal2)
and two CPC;Apc mice (adenoma1 and adenoma2; Figure 5).
We found that residual colonic adenomas fromCPC;Apcmice treated
with rapamycin revealed similar histology (H&E) to that of normal distal
colonic epithelium from untreated wild-type mice (scale bars, 100 μm;
Figure 6, A and B). In addition, the normal distal colonic epithelium
(control) in rapamycin-treated CPC;Apc mice showed no difference in
Figure 3. Validation of adenoma dimensions, growth, and regression. (A) Surface areas of adenomas measured on endoscopy in vivo
are compared with that evaluated postmortem with calipers (R2 = 0.84). (B) Volumes of adenomas measured on MRI in vivo are com-
pared with that evaluated postmortem with calipers (R2 = 0.81). (C) Comparison of adenoma growth rate in percent change (%Δ).
(D) Comparison of adenoma regression rate in percent change (%Δ) in response to rapamycin therapy.
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Figure 4. Rapamycin treatment inhibits mTOR signaling and attenuates cell growth in adenomas with Apc defect. (A) Representative low
magnification images show increased total β-catenin expression from adenoma derived from CPC;Apc mice in comparison to normal
(left panels; scale bar, 100 μm). Boxed regions are shown in high magnification (middle panels; scale bar, 20 μm). Increased expression
of phospho-S6 can be appreciated in adenoma in comparison to normal (right panels; scale bar, 100 μm). (B) Histology (H&E) of normal
distal colonic epithelium and adenoma treated with rapamycin (left panels) and vehicle (right panels; scale bars, 100 μm). The boxed areas
indicate regions of dysplasia that were further studied on IHC below. (C) Significant levels of total β-catenin expression were observed
from the adenomas in both rapamycin and vehicle-treated adenomas (left panels). Level of phospho-S6 ribosomal protein expression is
lower in residual adenoma from rapamycin-treated mouse compared to that for the vehicle-treated mouse (middle panels). A significant
reduction in the number of Ki67-labeled cells was observed in rapamycin-treated adenomas compared to vehicle-treated adenomas
(right panels; scale bars, 25 μm).
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Ki67 staining in comparison to vehicle-treated normal epithelium from
wild-type mouse (scale bars, 50 μm; Figure 6, C and D).
Discussion
Here, we demonstrate an optical MRI multimodal imaging strategy for
quantifying the growth and regression of colonic adenomas over time.
Optical imaging has superior spatial resolution in comparison to other
modalities, thus tumor dimensions can be measured with very high
accuracy and much smaller lesions can be detected. We have demon-
strated that our correlation of adenoma size with postmortem mea-
surements ex vivo is consistent with previously reported data on
lumen distention versus caliper measurements [11]. Because endo-
scopic images are collected as a two-dimensional (planar) projection
of a three-dimensional (volumetric) mass, validation of overall lesion
dimensions in vivo by an independent, previously established, imaging
modality, such as MRI, is needed. Whereas a previous study compared
estimates of lesion size on endoscopy with that obtained on MRI and
on necropsy [2], we show here how this multimodal imaging strategy
can be used effectively to monitor therapy. The ability to accurately
measure the lesion size on endoscopy is a powerful tool for evaluating
the efficacy of new drug therapies by enhancing the statistical power
of longitudinal investigations and minimizing the number of tumor-
bearing animals.
Furthermore, we showed that rapamycin therapy can greatly regress
or even completely eradicate established colonic adenomas, suggest-
ing that rapamycin or other mTOR inhibitors may be of clinical value
in management of colorectal adenomas in high-risk patients, such as
those with familial polyposis. Our results are consistent with previous
studies that show that mTOR inhibitors can suppress small intestinal
polyps derived from ApcMin mice [21,22]. However, our study is the
first to show that rapamycin can also effectively treat colon-specific
adenomas in a spontaneous model, which is different from results
shown previously where no inhibitory effects of rapamycin were found
for large intestinal adenomas [21]. The results between our study and
the study of Koehl et al. may reflect a difference in route (diet vs i.p.
injection) and in dosage achieved with rapamycin administration. In-
terestingly, whereas the study of Koehl et al. showed no accumulation
of β-catenin in rapamycin-treated adenomas compared to normal intes-
tinal epithelium [21], the residual neoplastic cells in rapamycin-treated
mice from our study still retained nuclear and cytoplasmic staining
of β-catenin and increased β-catenin levels in comparison to normal
colonic mucosa. Thus, our results suggest that rapamycin exerts its
inhibitory effects downstream of β-catenin accumulation. Consistent
with the study of Fujishita et al. [22], we showed that rapamycin
suppresses tumor growth through inhibition of cell proliferation.
Our study implies that the higher mTOR signaling found in colonic
Figure 5.Western blot analysis. Representative results are shown
for Western blot analysis of total β-catenin, phospho-S6K, total
S6K, phospho-S6, total S6, and β-actin from normal colon epithe-
lium from two wild-type (control) mice (normal1 and normal2)
and adenomas from two CPC NLS Cre Apcflox/+ mice (adenoma1
and adenoma2).
Figure 6. Colonic epithelial histology and cell proliferation in CPC;Apc mouse treated with rapamycin. (A) Residual colonic adenoma
from CPC;Apc mouse treated with rapamycin reveals similar histology (H&E) to that of (B) normal distal colonic epithelium from wild-
type mouse not treated with rapamycin (scale bars, 100 μm). (C) Rapamycin-treated normal distal colonic epithelium (control) from CPC;
Apc mouse shows no difference in Ki67 staining in comparison to (D) vehicle-treated normal colonic epithelium from wild-type mouse
(scale bars, 50 μm).
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adenomas with Apcmutation compared with normal colonic epithelium
may enhance susceptibility of adenomas to rapamycin treatment.
Consistent with the significant reduction of adenoma size in the
rapamycin-treated mice, about 50% of the adenomas remaining after
treatment revealed an epithelial histology largely resembling that of
normal-appearing colonic epithelium. Compared with vehicle-treated
adenomas with epithelial dysplasia throughout the lesions, the remain-
ing 50% of the rapamycin-treated adenomas that did not completely
regress showed a mixture of normal and dysplastic epithelium with
extensive lymphocyte infiltration. Interestingly, the residual dysplastic
regions in the rapamycin-treated adenomas still show positive nuclear
and cytoplasmic staining for β-catenin, suggesting that rapamycin
treatment does not interfere with β-catenin activation. Consistent with
rapamycin being an mTOR inhibitor, a significant reduction in phos-
phorylation of S6 ribosomal protein at Ser235/236 was observed in the
residual adenomatous epithelium in rapamycin-treated adenomas, sug-
gesting that the mTOR signaling was effectively inhibited by rapamycin
in these adenomas. In contrast to the intensive staining of Ki67 in vehicle-
treated adenomas, the number of Ki67-positive cells was greatly reduced
in rapamycin-treated adenomas, suggesting that rapamycin inhibits
tumor growth by reducing the cell proliferation.
Although normal colonic epithelium (control) also showed complete
loss of phospho-S6 protein expression after rapamycin treatment, no
difference was found in Ki67 staining in comparison to vehicle-treated
normal epithelium (Figure 6). mTOR pathway signaling in normal
distal colonic epithelium and adenomas was further compared to explore
the mechanism underlying the difference in susceptibility to rapamycin
therapy. Compared to normal colonic epithelium, protein expression
levels of both phospho-S6K and phospho-S6 were significantly in-
creased in adenomas with Apc defect. In addition, a much broader
and more intensive staining of phospho-S6 was observed in adenomas
compared to that found in normal colonic mucosa. These results imply
that higher mTOR pathway signaling observed in adenomas with Apc
defect may subject adenomas to “addiction” to mTOR signaling, thus
more sensitivity to the mTOR inhibitor rapamycin.
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